Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 3/20 | 0.52 |
| ▸ | PRCP | P42785 | 10/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.47 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.47 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12565411 | 0.97 | HPGDS (0.52) | HPGDSPRCPCYP3A4CYP2C9NR1I2 | |
| SCHEMBL7604983 | 0.97 | HPGDS (0.52) | HPGDSPRCPCYP3A4CYP2C9NR1I2 | |
| SCHEMBL9881654 | 0.96 | PRCP (0.50) | HPGDSPRCPCYP3A4CYP2C9NR1I2 | |
| SCHEMBL9977466 | 0.92 | HPGDS (0.51) | HPGDSPRCPCYP3A4CYP2C9NR1I2 | |
| SCHEMBL12565410 | 0.92 | HPGDS (0.51) | HPGDSPRCPCYP3A4CYP2C9NR1I2 | |
| SCHEMBL9881418 | 0.92 | PRCP (0.52) | HPGDSPRCPCYP3A4CYP2C9NR1I2 | |
| SCHEMBL12567836 | 0.91 | HPGDS (0.49) | HPGDSPRCPHCRTR1HCRTR2 | |
| SCHEMBL12565428 | 0.91 | HPGDS (0.49) | HPGDSPRCPHCRTR1HCRTR2 | |
| SCHEMBL10144864 | 0.91 | HPGDS (0.49) | HPGDSPRCPCYP3A4CYP2C9NR1I2 | |
| SCHEMBL10177193 | 0.90 | HPGDS (0.57) | HPGDSPRCPCYP3A4CYP2C9NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150057218-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS INC (US) | 2015-02-26 | — | — | US | disclosed |
| US-8921369-B2 | Inhibitors of HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-8877707-B2 | Inhibitors of HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20130203656-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130096101-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20120122864-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20110152246-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096101-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | HPGDS 2418/4885PRCP 309/4885CYP3A4 2817/4885 |
| US-20110152246-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, IRF3 | HPGDS 3219/4885PRCP 1157/4885CYP3A4 1292/4885 |
| US-20120122864-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | HPGDS 2085/4885PRCP 298/4885CYP3A4 2538/4885 |
| US-20150057218-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | HPGDS 2085/4885PRCP 298/4885CYP3A4 2538/4885 |
| US-20130203656-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | HPGDS 2085/4885PRCP 298/4885CYP3A4 2538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.